Recent advances include new immunotherapy drugs like nivolumab and pembrolizumab, targeted therapies like Erdafitinib for FGFR3 mutations, and antibody-drug conjugates such as enfortumab vedotin. The field is evolving with clinical trials exploring more targeted treatments and combinations to improve outcomes.